Transcriptional co‐factor Transducin beta‐like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy

Publisher： John Wiley & Sons Inc

E-ISSN： 1757-4684|7|8|1048-1062

ISSN： 1757-4676

Source： EMBO Molecular Medicine, Vol.7, Iss.8, 2015-08, pp. : 1048-1062

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting the insulin‐like growth factor‐1 receptor by picropodophyllin for lung cancer chemoprevention

By  

Molecular Carcinogenesis, Vol. 54, Iss. S1, 2015-06 ,pp. : E129-E137

John Wiley & Sons Inc

Access to resources Recommend Favorite

MicroRNA‐130a‐3p suppresses cell migration and invasion by inhibition of TBL1XR1‐mediated EMT in human gastric carcinoma

By  

Molecular Carcinogenesis, Vol. 57, Iss. 3, 2018-03 ,pp. : 383-392

John Wiley & Sons Inc

Access to resources Recommend Favorite

Apigenin suppresses insulin‐like growth factor I receptor signaling in human prostate cancer: An in vitro and in vivo study

By  

Molecular Carcinogenesis, Vol. 48, Iss. 3, 2009-03 ,pp. : 243-252

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacological targeting of the protein synthesis mTOR/4E‐BP1 pathway in cancer‐associated fibroblasts abrogates pancreatic tumour chemoresistance

By  

EMBO Molecular Medicine, Vol. 7, Iss. 6, 2015-06 ,pp. : 735-753

John Wiley & Sons Inc

Access to resources Recommend Favorite

EYA4 Acts as a New Tumor Suppressor Gene in Colorectal Cancer

By  

Molecular Carcinogenesis, Vol. 54, Iss. 12, 2015-12 ,pp. : 1748-1757

John Wiley & Sons Inc

Access to resources Recommend Favorite